Outpatient cancer treatment breakthrough: modified immune cells fight lymphoma
NCT ID NCT05459571
First seen Nov 01, 2025 · Last updated Apr 14, 2026 · Updated 24 times
Summary
This study tested a personalized cancer treatment called CAR-T cell therapy for people with aggressive lymphoma that has returned or resisted previous treatments. Researchers gave patients modified immune cells along with preventive steroids and monitored them in outpatient settings instead of requiring hospital stays. The main goals were to see if this approach was safe, reduced severe side effects, and effectively controlled the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California, 91010, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Henry-Joyce Cancer Clinic
Nashville, Tennessee, 37232, United States
-
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112, United States
-
Intermountain Healthcare
Murray, Utah, 84107, United States
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Methodist Healthcare System of San Antonio
San Antonio, Texas, 78229, United States
-
Oncology Hematology Care Clinical Trials, LLC
Cincinnati, Ohio, 45242, United States
-
Prisma Health - Upstate
Greenville, South Carolina, 29615, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
UCLA
Los Angeles, California, 90025, United States
-
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland, 21201, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23219, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.